Moderna Shares Surge 13% on Ebola Vaccine News
The WHO advisory group recommended adding Moderna's Ebola vaccine candidate to an ongoing trial in the Democratic Republic of the Congo.
Updated on Nov. 5, 2026 in Biotech
Moderna shares climbed 13.1% to close at $258.38 on Nov. 4 after the World Health Organization's Technical Advisory Group recommended adding the company's Ebola vaccine candidate, mRNA-1469, to the Tumaini trial. The Phase 2/3 study is taking place in the Democratic Republic of the Congo.
Why it matters
The recommendation extends Moderna's experimental Ebola vaccine into a larger clinical evaluation in an active outbreak setting. Investor reaction reflects the stock's rise above its Oct. 21 levels, with the company's third-quarter results due shortly after.
Moderna's Nov. 4 intraday high of $258.72 was 1.67% above its Oct. 21 intraday high of $254.48, and the close was 5.11% above the Oct. 21 close of $245.81. The source provides no technical specifications for mRNA-1469 or the Tumaini trial design beyond its Phase 2/3 classification.
The players
Moderna
Moderna is a biotechnology company that develops mRNA-based vaccines and therapeutics, including its Ebola vaccine candidate mRNA-1469.
World Health Organization
The World Health Organization is the United Nations agency that coordinates international public health responses and vaccine prioritization efforts.
The details
The WHO Technical Advisory Group on Candidate Vaccine Prioritization recommended adding mRNA-1469 to the Tumaini trial, a Phase 2/3 study in the Democratic Republic of the Congo. Separately, early clinical data for mRNA-2808, a multiple myeloma therapy, are slated for an oral presentation at the American Society of Hematology annual meeting.
Timeline
Oct. 21, 2026: Reference date for Moderna's prior-session intraday high and closing price.
Nov. 4, 2026: Shares rose 13.1% to close at $258.38.
Nov. 6, 2026: Moderna reports third-quarter results and holds a conference call at 8 a.m. ET.
The Tech Race
The recommendation places Moderna's mRNA platform into the WHO's candidate prioritization process for Ebola, a disease for which the source does not describe prior vaccine options. The company's stock gain reflects investor attention to its mRNA pipeline relative to its October trading levels.
The source does not describe any change to vaccine availability, pricing, or access for U.S. consumers. The near-term reader-facing development is the Nov. 6 earnings report, which may update the company's guidance on its pipeline.
The takeaway
Investor attention to Moderna in early November centered on a late-October-to-early-November rise in share price alongside a WHO trial recommendation. The next concrete data point is the Nov. 6 third-quarter report.
What happens next
Moderna is scheduled to report third-quarter results on Friday, Nov. 6, followed by a conference call at 8 a.m. ET.
Further reading
For related coverage, see Biotech in the Tech section.
Source note: This article includes information reported by TokenPost.
